Insmed | INSM - Gross Profit On Sales

Stock Price
136.47
Daily Change
1.53 1.13%
Monthly
-10.99%
Yearly
89.54%
Q2 Forecast
132.28

Insmed reported $217.69M in Gross Profit on Sales for its fiscal quarter ending in December of 2025.





Gross Profit On Sales Change Date
BioMarin Pharmaceutical USD 713.01M 81.81M Dec/2025
Cytokinetics USD 17.76M 15.82M Dec/2025
DBV Technologies USD 2.77M 33.21M Sep/2025
Gilead Sciences USD 6.31B 106M Dec/2025
Heron Therapeutics USD 29.47M 3.17M Dec/2025
Insmed USD 217.69M 106.25M Dec/2025
Novartis USD 10.82B 694M Sep/2025
Regeneron Pharmaceuticals USD 3.3B 67M Dec/2025
Sarepta Therapeutics USD 43.55M 204.36M Dec/2025
Ultragenyx Pharmaceutical USD 178M 46.06M Dec/2025
Vertex Pharmaceuticals USD 2.72B 62.4M Dec/2025